AP Biosciences Inc (TPEX:6945)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
110.50
-1.50 (-1.34%)
Oct 9, 2025, 2:51 PM CST
-1.34%
Market Cap9.41B
Revenue (ttm)n/a
Net Income (ttm)-394.19M
Shares Out85.11M
EPS (ttm)-4.64
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume278,085
Average Volume204,665
Open112.00
Previous Close112.00
Day's Range108.50 - 112.00
52-Week Range36.30 - 178.00
Beta0.55
RSI43.27
Earnings DateNov 12, 2025

About AP Biosciences

AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast ca... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 37
Stock Exchange Taipei Exchange
Ticker Symbol 6945
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.